These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 28422287)

  • 21. GPX3 promoter methylation predicts platinum sensitivity in colorectal cancer.
    Pelosof L; Yerram S; Armstrong T; Chu N; Danilova L; Yanagisawa B; Hidalgo M; Azad N; Herman JG
    Epigenetics; 2017 Jul; 12(7):540-550. PubMed ID: 27918237
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II study of irinotecan/S-1 combination chemotherapy for patients with oxaliplatin-refractory colorectal cancer.
    Oh SY; Ju YT; Choi SK; Ha CY; Lee WS; Kim HG; Lee GW; Kwon HC; Kang JH
    Invest New Drugs; 2011 Oct; 29(5):1050-6. PubMed ID: 20238142
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study.
    Suenaga M; Mizunuma N; Matsusaka S; Shinozaki E; Ozaka M; Ogura M; Yamaguchi T
    Drug Des Devel Ther; 2015; 9():3099-108. PubMed ID: 26124634
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab.
    Prewett M; Deevi DS; Bassi R; Fan F; Ellis LM; Hicklin DJ; Tonra JR
    Clin Cancer Res; 2007 Dec; 13(24):7432-40. PubMed ID: 18094427
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [KRAS mutation does not influence oxaliplatin or irinotecan efficacy, in association with bevacizumab, in first line treatment of metastatic colorectal cancer].
    Cabart M; Frénel JS; Campion L; Ramée JF; Dupuis O; Senellart H; Hiret S; Douillard JY; Bennouna J
    Bull Cancer; 2016 Jun; 103(6):541-51. PubMed ID: 27155924
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictive impact of genetic polymorphisms in DNA repair genes on susceptibility and therapeutic outcomes to colorectal cancer patients.
    Sun K; Gong A; Liang P
    Tumour Biol; 2015 Mar; 36(3):1549-59. PubMed ID: 25355595
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PKM2 Subcellular Localization Is Involved in Oxaliplatin Resistance Acquisition in HT29 Human Colorectal Cancer Cell Lines.
    Ginés A; Bystrup S; Ruiz de Porras V; Guardia C; Musulén E; Martínez-Cardús A; Manzano JL; Layos L; Abad A; Martínez-Balibrea E
    PLoS One; 2015; 10(5):e0123830. PubMed ID: 25955657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic and predictive significance of long interspersed nucleotide element-1 methylation in advanced-stage colorectal cancer.
    Kaneko M; Kotake M; Bando H; Yamada T; Takemura H; Minamoto T
    BMC Cancer; 2016 Dec; 16(1):945. PubMed ID: 27955637
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug resistance, predictive markers and pharmacogenomics in colorectal cancer.
    Longley DB; Allen WL; Johnston PG
    Biochim Biophys Acta; 2006 Dec; 1766(2):184-96. PubMed ID: 16973289
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts.
    Nukatsuka M; Nakagawa F; Takechi T
    Anticancer Res; 2015 Sep; 35(9):4605-15. PubMed ID: 26254349
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of genomic markers in colorectal cancer treatment.
    Allen WL; Johnston PG
    J Clin Oncol; 2005 Jul; 23(20):4545-52. PubMed ID: 16002846
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer.
    Cortejoso L; García MI; García-Alfonso P; González-Haba E; Escolar F; Sanjurjo M; López-Fernández LA
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1463-72. PubMed ID: 23543295
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ATM Is Required for the Repair of Oxaliplatin-Induced DNA Damage in Colorectal Cancer.
    Bakkenist CJ; Lee JJ; Schmitz JC
    Clin Colorectal Cancer; 2018 Dec; 17(4):255-257. PubMed ID: 30316683
    [No Abstract]   [Full Text] [Related]  

  • 34. Oxaliplatin: a novel platinum analog with activity in colorectal cancer.
    Berg D
    Oncol Nurs Forum; 2003; 30(6):957-66. PubMed ID: 14603353
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oxaliplatin: mechanism of action and antineoplastic activity.
    Raymond E; Faivre S; Woynarowski JM; Chaney SG
    Semin Oncol; 1998 Apr; 25(2 Suppl 5):4-12. PubMed ID: 9609103
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Single nucleotide polymorphisms in nucleotide excision repair genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/fluoropyrimidine.
    Monzo M; Moreno I; Navarro A; Ibeas R; Artells R; Gel B; Martinez F; Moreno J; Hernandez R; Navarro-Vigo M
    Oncology; 2007; 72(5-6):364-70. PubMed ID: 18204222
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic variation in the DNA repair pathway as a potential determinant of response to platinum-based chemotherapy in breast cancer.
    Beheshti F; Hassanian SM; Khazaei M; Hosseini M; ShahidSales S; Hasanzadeh M; Maftouh M; Ferns GA; Avan A
    J Cell Physiol; 2018 Apr; 233(4):2752-2758. PubMed ID: 28696006
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Colorectal cancer surgery in portal hypertensive patients: does adjuvant oxaliplatin affect prognosis?
    Madbouly KM; Hussein AM; Zeid A
    Dis Colon Rectum; 2013 May; 56(5):577-85. PubMed ID: 23575396
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oxaliplatin in the treatment of colorectal cancer.
    Kim GP; Erlichman C
    Expert Opin Drug Metab Toxicol; 2007 Apr; 3(2):281-94. PubMed ID: 17428157
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Functional genomics reveals diverse cellular processes that modulate tumor cell response to oxaliplatin.
    Harradine KA; Kassner M; Chow D; Aziz M; Von Hoff DD; Baker JB; Yin H; Pelham RJ
    Mol Cancer Res; 2011 Feb; 9(2):173-82. PubMed ID: 21169384
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.